There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s “Doctored.” ...

Research supporting the amyloid hypothesis—the idea that Alzheimer's is caused by a buildup of amyloid plaques in the ...

Alzheimer's disease, a type of dementia that profoundly alters a person’s memory and cognitive function, affects an estimated 6.7 million U.S. adults at least 65 years old, according to the ...

Scientists have identified a biomarker for Alzheimer's that may help doctors spot the early signs of protein buildup in the ...

Neurofibrillary tangles (NFTs) are a hallmark of Alzheimer’s disease, formed by the accumulation of tau protein into ...

New drugs for early Alzheimer’s disease may allow people to live without help for up to 39 additional months, a new study ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

The finding may open a whole new world in the study of Alzheimer's disease, said biophysicist Aneta Stefanovska.

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

The test could help identify one key Alzheimer's biomarker, tau protein, before it shows up in brain. Here's what experts say ...

The first participants in an international clinical trial aimed at preventing Alzheimer’s disease in young adults at high ...

Jan. 15, 2025 — Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that accumulate in the brain, but new research points to a ...